Company news

Stoke Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2025

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 9, 2025

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 9, 2025

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2025

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 12, 2025

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

March 17, 2025

Stoke Therapeutics Announces CEO Transition

March 17, 2025

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

February 25, 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 17, 2025

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

January 6, 2025

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

January 5, 2025

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

December 5, 2024

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

December 3, 2024

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

December 1, 2024

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 4, 2024

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

September 9, 2024

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

September 3, 2024

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

September 2, 2024

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

September 2, 2024

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 6, 2024

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

June 2, 2024

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

May 5, 2024

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

April 28, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 16, 2024

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 3, 2024

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 26, 2024

Stoke Therapeutics Announces Proposed Public Offering

March 25, 2024

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 24, 2024

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

March 24, 2024

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

January 7, 2024

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

November 30, 2023

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

November 20, 2023

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

September 19, 2023

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

September 4, 2023

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 24, 2023

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 20, 2023

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

May 2, 2023

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 24, 2023

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 14, 2023

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 5, 2023

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 26, 2023

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 8, 2023

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

December 1, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.